|
|
|
|
|
|
Prospective Multicentric Randomized Study of Glivec® in Advanced Gastrointestinal Stromal Tumors Expressing c-Kit: Interruption After 5 Years vs Maintenance |
3 |
| |
|
|
|
|
|
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate. |
3 |
| |
|
|
|
|
|
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients |
3 |
| |
|
|
|
|
|
Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour |
3 |
| |
|
|
|
|
|
Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST) |
3 |
| |
|
|
|
|
|
Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1) |
3 |
| |
|
|
|
|
|
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors |
2 |
| |
|
|
|
|
|
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor |
2 |
| |
|
|
|
|
|
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST) |
2 |
| |
|
|
|
|
|
Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor |
2 |
| |
|
|
|
|
|
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) |
2 |
| |
|
|
|
|
|
REGISTER: A multicentre phase 2 study of risk evaluation in GIST with selective therapy escalation for response |
2 |
| |
|
|
|
|
|
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. (OPEN) |
2 |
| |
|
|
|
|
|
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor |
2 |
| |
|
|
|
|
|
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) |
2 |
| |
|
|
|
|
|
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) |
2 |
| |
|
|
|
|
|
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor |
2 |
| |
|
|
|
|
|
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate |
2 |
| |
|
|
|
|
|
Sorafenib for Imatinib/Sunitinib-failed GIST |
2 |
| |
|
|
|
|
|
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) |
2 |
| |
|
|
|
|
|
Evaluation of Patients With Bulky GIST Using Sunitinib |
2 |
| |
|
|
|
|
|
Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor |
2 |
| |
|
|
|
|
|
LBH589 Plus Imatinib |
1 |
| |
|
|
|
|
|
Radiation Therapy as Palliative Treatment of GIST (GIST-RT) |
1 |
| |
|
|
|
|
|
Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST) |
|
| |
|
|
|
|
|
Gastrointestinal Stromal Tumors (GIST) Registry |
|
| |
|
|
|
|
|
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors |
4 |
| |
|
|
|
|
|
Treatment of Patients With RAD001 Who Have Progressive Sarcoma |
2 |
| |
|
|
|
|
|
Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Imatinib Mesylate Refractory Advanced/Metastatic Malignant GIST |
2 |
| |
|
|
|
|
|
Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery |
1 |
| |
|
|
|
|
|
Imatinib + IL-2 |
1 |
| |
|
|
|
|
|
Safety Study of PLX108-01 in Patients With Solid Tumors |
1 |
| |
|
|
|
|
|
A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors |
1 |
| |
|
|
|
|
|
Study on the Influence of Sunitinib and Sorafenib on Fatigue, Quality of Life and Depression in Patients With Metastatic Renal Cell Cancer or Gastrointestinal Stromal Tumor (GIST) |
|
| |
|
|
|
|
|
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma |
2 |
| |
|
|
|
|
|
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients. |
1 |
| |
|
|
|
|
|
A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer |
1 |
| |
|
|
|
|
|
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered Daily in Patients With Locally Advanced or Metastatic Solid Tumors |
1 |
| |
|
|
|
|
|
A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma |
1 |
| |
|
|
|
|
|
A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma |
1 |
| |
|
|
|
|
|
AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors |
2 |
| |
|
|
|
|
|
Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer |
2 |
| |
|
|
|
|
|
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors |
1 |
| |
|
|
|
|
|
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer |
1 |
| |
|
|
|
|
|
Administration of BIIB028 to Subjects With Solid Tumors |
1 |
| |
|
|
|
|
|
A Phase IA, Multi-Center, Open-Label, Dose- Escalation Study of BKM120, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients with Advanced Solid Malignancies |
1 |
| |
|
|
|
|
|
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors |
1 |
| |
|
|
|
|
|
A Phase I Trial of Bortezomib and Sunitinib |
1 |
| |
|
|
|
|
|
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable |
1 |
| |
|
|
|
|
|
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable |
1 |
| |
|
|
|